Press Releases
- December 17, 2012
- Naurex Completes $38 Million Series B Financing
- December 6, 2012
- Phase II Data Presented at ANCP 2012 Shows Novel Antidepressant GLYX-13 Significantly Reduces Depression Scores Within Hours
- November 7, 2011
- Naurex’s Novel Antidepressant GLYX-13 Recognized as One of Windhover’s 2011 Top 10 Neuroscience Projects to Watch
- June 22, 2011
- Naurex Initiates Phase II Clinical Trial of Novel Antidepressant GLYX-13 In Treatment-Resistant Depression
- May 11, 2011
- Naurex Completes $18 Million Series A Financing
- December 7, 2010
- New Preclinical Data Confirm Naurex’s Novel Antidepressant GLYX-13 Appears Free of the Behavioral Impairment and Abuse Potential Seen With Ketamine
- November 17, 2010
- Preclinical Data at Neuroscience 2010 Show Naurex's Novel Antidepressant GLYX-13 Shares Key Efficacy Mechanisms With Ketamine
- August 31, 2010
- Naurex’s Novel Antidepressant GLYX-13 Recognized as One of Windhover's Top 10 Neuroscience Projects to Watch
- June 17, 2010
- Naurex Inc. Presents Positive Clinical Data on Novel Mechanism Antidepressant Candidate GLYX-13 at NCDEU 50th Anniversary Meeting
- February 10, 2010
- Naurex Inc. Reports Positive Top-Line Phase I Results for its Novel Mechanism NMDA Receptor Modulator GLYX-13 in Treatment-Resistant Depression
- December 16, 2009
- Naurex Inc. Announces Presentation of Preclinical Data Showing its Novel Mechanism NMDA Modulator Exhibits Robust and Rapid-Onset Antidepressant Activity with No Signs of Classic NMDA-Associated Side Effects
- December 16, 2009
- Naurex Inc. Initiates Phase I Clinical Trial of its Novel Mechanism NMDA Modulator GLYX-13 in Treatment-Resistant Depression
|
|
Naurex in the News
- New Class of Drugs Could Offer Depression Breakthrough, December 6, 2012 – CBS Evening News
(click here for a pdf copy of the broadcast story)
- Rapid Antidepressant Effects of Ketamine Ignite Drug Discovery, January 7, 2013 – Nature Medicine
(click here for a pdf copy of the article)
- Company Spotlight (Naurex: A Leader in the Race for a Fast Acting Antidepressant), January 2013 – Neurotech Insights (Subscription required)
- News Headlines (Naurex & GLYX-13), January 2013 – NeuroPerspective (Subscription required)
- Baxter Joins Big Pharma Funds on $38M B Round For Naurex Anti-Depression R&D, December 17, 2012 – FierceBiotech
- Antidepressant GLYX-13 Shows Promise in Phase IIa, December 7, 2012 – BioWorld Today (Subscription required)
- NeuroPerspective: Depression (Naurex & GLYX 13), December 2012 – NeuroPerspective (Subscription required)
|
